Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Raphael lives with stage 5 chronic kidney disease. He didn’t join the run to chase a medal or a record. He joined because he ...

Neither delivery of electronic nudge letters nor letters to general practice increase uptake of guideline-directed medical ...

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney ...

The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

Investing.com -- Mineralys Therapeutics Inc (NASDAQ: MLYS) stock surged 7.9% after reporting positive topline data from its Phase 2 Explore-CKD trial for lorundrostat in patients with hypertension and ...

Steve Hansgen, whose bass lines propelled Minor Threat’s “Out of Step” album, says he’s hopeful he’ll get a transplant to deal with his Stage 4 kidney disease.

Our body's kidneys are sophisticated organs that filter out waste and moisture in the blood and preserve necessary substances ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...